{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kiesel BF"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["e5455"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9731518"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(11)"],"pubmed_abstract":["Ataxia-telangiectasia-mutated and Rad3-related (ATR) is master regulator of the DNA-damage response that, through multiple mechanisms, can promote cancer cell survival in response to replication stress from sources, including chemotherapy and radiation. Elimusertib (BAY-1895344) is an orally available small-molecule ATR inhibitor currently in preclinical and clinical development for cancer treatment. To support these studies and define elimusertib pharmacokinetics, we developed a HPLC-MS method for its quantitation. A 50-μL volume of plasma was subjected to acetonitrile protein precipitation and then chromatographic separation using a Phenomenex Polar-RP column (2 × 50 mm, 4 μm) and a gradient mobile phase consisting of 0.1% formic acid in acetonitrile and water during a 7-min run time. Ma"],"journal":["Biomedical chromatography : BMC"],"pubmed_title":["Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS."],"pmcid":["PMC9731518"],"funding_grant_id":["UM1 CA186690","P30 CA047904","U24 CA247643","R50 CA211241","P30 CA47904"],"pubmed_authors":["Krishnamurthy A","Gore S","Kiesel BF","Beumer JH","Parise RA"],"additional_accession":[]},"is_claimable":false,"name":"Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS.","description":"Ataxia-telangiectasia-mutated and Rad3-related (ATR) is master regulator of the DNA-damage response that, through multiple mechanisms, can promote cancer cell survival in response to replication stress from sources, including chemotherapy and radiation. Elimusertib (BAY-1895344) is an orally available small-molecule ATR inhibitor currently in preclinical and clinical development for cancer treatment. To support these studies and define elimusertib pharmacokinetics, we developed a HPLC-MS method for its quantitation. A 50-μL volume of plasma was subjected to acetonitrile protein precipitation and then chromatographic separation using a Phenomenex Polar-RP column (2 × 50 mm, 4 μm) and a gradient mobile phase consisting of 0.1% formic acid in acetonitrile and water during a 7-min run time. Ma","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-28T02:13:20.409Z","creation":"2025-04-04T03:00:31.533Z"},"accession":"S-EPMC9731518","cross_references":{"pubmed":["35876841"],"doi":["10.1002/bmc.5455"]}}